[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pancreatic-cystic-neoplasms\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pancreatic-cystic-neoplasms":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100634161","endoscopic-ultrasound-guided-radiofrequency-ablation-for-pancreatic-cystic-neoplasms-and-pancreatic-neuroendocrine-tumors-100634161",false,"NCT07536087","Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Pancreatic Neuroendocrine Tumors","Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Cystic Neoplasms and Neuroendocrine Tumors","Inclusion Criteria:\n\n* Consensual indication to EUS-guided RFA treatment made in a multidisciplinary team\n* Capability of giving informed consent PCN Inoperability or refusal of surgery\n* Branch duct IPMN (BD-IPMN) with worrisome features:\n* Jaundice\n* High grade dysplasia or cancer\n* Solid mass\u002Fnodule \\> 5mm\n* Main pancreatic duct dilation \\> 10mm Or at least one (patients without comorbidities) or at least two (patient with comorbidities) of the following risk features:\n* CA 19-9\\> 37 U\u002Fml\n* Increase in size \\> 5mm\u002Fyear\n* Dilation of the main pancreatic duct between 5-10mm\n* Size ≥ 40mm\n* Symptoms (new onset of diabetes, acute pancreatitis)\n* Nodule \\\u003C 5mm Pancreatic NET\n* Size \\\u003C 2 cm\n* Histological proof in non-functional lesions\u002Fhistological proof or clinical proof in functional lesions\n* 68Ga-DOTATATE PET\u002FCT positive for a pancreatic lesion and negative for lymph nodes, liver, and other distant metastases\n* G1 or G2 (\\\u003C5 %) histology\n\nExclusion Criteria:\n\n* Known bleeding disorder that cannot be sufficiently corrected with medication\n* Use of anticoagulants that cannot be discontinued\n* Physical and\u002For psychological inability to understand the aims of the research and to adequately cooperate\n* Pregnancy\n* Inability to sign the informed consent","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","The primary aim of this study is to evaluate the technical feasibility and effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) in the treatment of pancreatic cystic neoplasms (PCNs) and pancreatic neuroendocrine tumors (pNETs) in patients who are not suitable candidates for surgical treatment or who refuse surgery.\n\nEUS-RFA, as a minimally invasive therapeutic option, may potentially reduce the need for intensive imaging surveillance, prevent further progression of these lesions, and serve as a bridging therapy in selected patients for whom surgical intervention may be considered in the future. At the same time, EUS-RFA could contribute to reducing overtreatment, thereby lowering the risk of complications associated with surgical procedures and leading to an overall reduction in healthcare costs.\n\nThe secondary objectives of the study are to evaluate the safety profile of EUS-RFA, including the incidence and severity of adverse events both in the early postoperative period and during the first year of follow-up, as well as to assess the long-term efficacy of EUS-RFA, including disease progression.",[26,27,28],"Endoscopic Ultrasound-Guided Radiofrequency Ablation","Pancreatic Neuroendocrine Tumors (pNET)","Pancreatic Cystic Neoplasms",[30,31,32,33,34,35],"Pancreatic Cystic Neoplasm","Intraductal papillary mucinous neoplasm","EUS-guided RFA","Pancreas","Neuroendocrine tumor","Radiofrequency ablation","RECRUITING","2026-04-11",{"date":39,"type":40},"2026-04-17","ACTUAL",{"date":37,"type":40},{"date":43,"type":20},"2029-12-31",{"name":45,"class":46},"Institute for Clinical and Experimental Medicine","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":47},"100599661","inverted--anastomosis-in-laparoscopic-duodenum-preserving-pancreatic-head-resection-or-laparoscopic-central-pancreatectomy-100599661","NCT07087392","Inverted-Ω Anastomosis in Laparoscopic Duodenum-Preserving Pancreatic Head Resection or Laparoscopic Central Pancreatectomy","Modified Digestive Tract Reconstruction in Laparoscopic Duodenum-Preserving Pancreatic Head Resection or Laparoscopic Central Pancreatectomy: Inverted-Ω Anastomosis","Inclusion Criteria:\n\n1. Age 18 to 75 years old, gender not limited;\n2. Patients diagnosed with benign or low-grade malignant tumors in the head or middle section of the pancreas by CT or MRI;\n3. ECOG score 0-1.\n\nExclusion Criteria:\n\n1. Those with severe heart, liver or kidney insufficiency, or those who are assessed as intolerant to surgery or anesthesia, or those with ASA grade \\> 3;\n2. Patients with a history of or concurrent other malignant tumors, or other serious infections or infectious diseases, or those who are unable to complete the anastomosis surgery;\n3. Uncontrollable concomitant diseases, including but not limited to severe coronary artery disease, COPD or asthma, uncontrollable cerebrovascular diseases, symptomatic congestive failure, unstable angina pectoris, arrhythmia, or other diseases that the researchers consider ineligible for enrollment;\n4. Patients who have undergone other upper abdominal surgeries and digestive tract reconstruction procedures in the past;\n5. Patients requiring combined organ resection;\n6. Preoperative assessment suggested that the patient might have factors such as active ulcers and bleeding in the digestive tract;\n7. Pregnant and lactating women;\n8. Any uncertain factors that have an impact on the patient's safety or compliance.","75 Years",{"count":57,"type":20},20,[23],"The goal of this clinical trial is to learn if inverted-Ω anastomosis after pancreatic head resection or mid-pancreatectomy works in benign or low-grade malignant tumor. It will also learn about the safety and feasibility of inverted-Ω anastomosis. The main questions it aims to answer are:\n\n1. Does inverted-Ω anastomosis operate safely? (operative time, blood loss, transfusion and conversion rate)\n2. What is the incidence and severity of postoperative complications in inverted -Ω anastomosis? What advantages does it have over conventional anastomosis methods such as roux-en-y？",[28],"NOT_YET_RECRUITING","2025-07-24",{"date":64,"type":40},"2025-07-28",{"date":66,"type":20},"2025-07-20",{"date":68,"type":20},"2028-07-20",{"name":70,"class":71},"West China Hospital","OTHER"]